Clinical trial
Social Anxiety Disorder Study Of Paroxetine
NCT00318669 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00318669 |
|---|---|
| Title | Social Anxiety Disorder Study Of Paroxetine |
| Official title | Clinical Evaluation of BRL29060A (Paroxetine Hydrochloride Hydrate) in Social Phobia/Social Anxiety Disorder (SAD) -A Double-blind, Placebo-controlled Study- <Phase III Study> |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Social Phobia |
| Intervention type | Drug |
| Interventions | Paroxetine hydrochloride hydrate |
| Enrollment | 390 |
| Start date | Dec 1, 2005 |
| Primary completion | Nov 1, 2006 |
| Completion | Nov 1, 2006 |
| First posted | Apr 27, 2006 |
| Last update posted | Apr 15, 2013 |
| Countries | Japan |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: